Hereditary predispositions to colorectal cancer;Prédispositions héréditaires au cancer colorecta

Gastroenterologie Clinique et Biologique

Volumn 29, Issue 6-7, 2005, Pages 701-710

  Bonaïti Pellié, Catherine ^a   Eisinger, François ^b   Feingold, Josué ^c   Frébourg, Thierry ^d   Grandjouan, Sophie ^e   Lasset, Christine ^f   Laurent Puig, Pierre ^g   Lecuru, Fabrice ^h   Millat, Bertrand ⁱ   Sobol, Hagay ^b   Thomas, Gilles ^g   Olschwang, Sylviane ^g  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

^e Institut Cochin   (France)

^f CENTRE LÉON BÉRARD   (France)

^g INSERM   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL;

CANCER CHEMOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; COLON RESECTION; COLORECTAL CANCER; FAMILIAL CANCER; GENE DELETION; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; PHENOTYPE; REVIEW;

EID: 21844458943     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(05)82159-1     Document Type: Article

References (97)

1. Bonaïti-Pellié C. Genetic risk factors in colorectal cancer. Eur J Cancer Prev 1999;8:S27-32.
2. Benhamiche-Bouvier AM, Clinard F, Phelip JM, Rassiat E, Faivre J. Colorectal cancer prevalence in France. Eur J Cancer Prev 2000;9: 303-07.
3. Andrieu N, Launoy G, Guillois R, Ory-Paoletti C, Gignoux M. Familial relative risk of colorectal cancer: a population-based study. Eur J Cancer 2003;39:1904-11.
4. Warthin AS. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch Intern Med 1913;12:546-55.
5. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 1966;117:206-12.
6. Vasen H, Mecklin JP, Meera-Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5.
7. Olschwang S. Germline mutation and genome instability. Eur J Cancer Prev 1999;8:S33-7.
8. Rodrigues-Bigas M, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.
9. Vasen H, Watson P, Mecklin J-P, Lynch HT. New clinical criteria for hereditary nonpolyposis Colorectal cancer (HNPCC, Lynch Syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999;116:1453-8.
10. Riegler G, Savastano A, Selvaggi F, Ciocano R, Martino R, Riccio G, et al. Prevalence of HNPCC in a series of consecutive patients on the first endoscopic diagnosis of colorectal cancer: a multicenter study. The Italian Collaborative Group. Endoscopy 1999;31:337-41.
11. Peel DJ, Ziogas A, Fox EA, Gildea M, Laham B, Clements E, et al. Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. J Natl Cancer Inst 2000;92:151-722.
12. Percepese A, Borghi F, Menigatti M, Losi L, Foroni M, Di Gregorio C, et al. Molecular screening for HNPCC: a prospective, population-based study. J Clin Oncol 2001;19:3944-50.
13. Raedle J, Trojan J, Brieger A, Weber N, Schäfer D, Plotz G. Bethesda guidelines: relations to microsatellite intability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med 2001; 135:566-76.
14. Katballe N, Christensen M, Wilkman FP, Orntoft TF, Laurberg S. Frequency of HNPCC in Danish colorectal cancer patients. Gut 2002;50: 43-51.
15. Hemminki K, Li X. Familial colorectal adenocarcinoma and HNPCC: a nationwide epidemiological study from Sweden. Br J Cancer 2001; 84:969-74.
16. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000;18:2193-200.
17. Olschwang S, Bonaïti C, Feingold J, Frébourg T, Grandjouan S, Lasset C, et al. Identification et prise en charge du syndrome HNPCC (Hereditary NonPolyposis Colorectal Cancer), prédisposition héréditaire aux cancers du côlon, du rectum et de l'endomètre. Bull Cancer 2004;91: 303-15
18. Lynch HT, Kimberling W, Albano WA. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer 1985;56:934-8.
19. Watson P et Lynch H. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71:677-85.
20. Vasen H, Wijnen JT, Menko FH. Cancer risk in families of patients with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-7.
21. Aarnio M, Sankila R, Pukkala E. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-8.
22. Mecklin JP, Järvinen HJ, Peltokallio P. Cancer family syndrome: genetic analysis of 22 Finnish kindreds. Gastroenterology 1986;90:328-33.
23. Aarnio M, Mecklin JP, Aaltonen LA. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer (Pred Oncol) 1995;64:430-3.
24. Voskuil DW, Vasen HF, Kampman E, van't Veer P. Colorectal cancer risk in HNPCC families: development during lifetime and in successive generations. National Collaborative Group on HNPCC. Int J Cancer 1997;72:205-9.
25. Lin KM, Shashidharan M, Thorson AG. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 1998;2:67-71.
26. Frogatt N, Green J, Brassett C, Evans DGR, Bishop DT, Kolodner R. et al. A common MSH2 mutation in English and North American HN-PCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. J Med Genet 1999;36:97-102.
27. Green J, O'Driscoll M, Barnes, Maher ER, Bridge P, Shields K, et al. A. Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation. Dis Colon Rectum 2002;45:1223-32
28. Carayol J, Khlat M, Maccario J, Bonaïti-Pellié C. Hereditary non-polyposis colorectal cancer: current risks of colorectal cancer largely overestimated. J Med Genet 2002;39:335-9.
29. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10.
30. Parc Y, Boisson C, Thomas G, Olschwang S. Cancer risk in 348 French MSH2 or MLH1 gene carriers. J Med Genet 2003;40:208-13.
31. Peltomäki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993;260:810-2.
32. Lindblom A, Tannergard P, Werelius B, Nordenskjold M. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet 1993;5:279-82.
33. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
34. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-38.
35. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK. Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis côlon cancer. Nature 1994;368: 258-61.
36. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, et al. Mutation of a mutL homolog in hereditary côlon cancer. Science 1994;263:1625-9.
37. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M. Germline mutation of MSH6 as the cause of hereditary non-polyposis colorectal cancer. Nat Genet 1997;17:271-2.
38. Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997;57:3920-3.
39. Peltomäki P, Vasen H. The International Collaborative Groupe on Hereditary Nonpolyposis Colorectal Cancer: Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology 1997;113:1146-58.
40. Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der Klift H, Mulder A, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998;20: 511-8.
41. Charbonnier F, Olschwang S, Wang Q, Boisson C, Martin C, Buisine MP, et al. MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary non-polyposis colorectal cancer. Cancer Res 2002;62:848-53.
42. Berends MJ, Wu Y, Sijmons RH, Mensink RG, van der Sluis T, Hordijk-Hos JM, et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 2002;70:26-37.
43. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-7.
44. Liu T, Wahlberg S, Burek E, Lindblom P, Rubio C, Lindblom A. Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer. Genes Chromosomes Cancer 2000;27:17-25.
45. Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis côlon cancer families. Cancer Res 2002;62:3485-92.
46. Christensen M, Katballe N, Wikman F, Primdahl H, Sorensen FB, Laurberg S, et al. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing. Cancer 2002;95:2422-30.
47. Terdiman JP, Levin TR, Allen BA, Gum JR Jr, Fishbach A, Conrad PG. et al. Hereditary nonpolyposis colorectal cancer in young colorectal cancer patients: high-risk clinic versus population-based registry. Gastroenterology 2002;122:940-7.
48. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
49. Umar A, Boland R, Terdiman J, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for HNPCC and microsatellite instability. J Natl Cancer Inst 2004;96:261-8.
50. Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999;45:409-15.
51. Ward R, Tomlinson I, O'Connor T, Norrie M, Wu R, Hawkins N. Microsatellite instability and clinicopathological features of sporadic colorectal cancer. Gut 2001;48:821-9.
52. Lanza G, Gafa R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol 2002;15:741-9.
53. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:897-9.
54. Rigau V, Sebbagh N, Olschwang S, Paraf F, Mourra N, Parc Y. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 correction of hMLH6] immunostaining. Arch Pathol Lab Med 2003;127:694-700.
55. Herman JG, Umar A, Polyak K, Grafe JR, Ahuja N, Issa JPJ. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870-5.
56. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomäki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000;156:1773-9.
57. Wheeler JM, Loukola A, Aaltonen LA, Mortensen NJ, Bodmer WF. The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers. J Med Genet 2000;37:588-92.
58. Cunningham JM, Kim CY, Chrisensen ER, Tester DJ, Parc Y, Burgart LJ. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001;69:780-90.
59. Nakagawa H, Nuovo GJ, Zervos EE, Martin EW Jr, Salovaara R, Aaltonen LA. Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001;61:6991-5.
60. Kerber RA, Slattery ML. Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 1997;146:244-8.
61. Bergmann MM, Calle EE, Mervis CA, Miracle-McMahill HL, Thun MJ, Heath CW. Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol 1998;147:556-62.
62. Ruo L, Cellini C, La-Calle JP, Jr., Murray M, Thaler HT, Quan SH, et al. Limitations of family cancer history assessment at initial surgical consultation. Dis Colon Rectum 2001;44:98-103.
63. Love RR, Evans AM, Josten DM. The accuracy of patient reports of a family history of cancer. J Chronic Dis 1985;38:289-93.
64. Bondy ML, Strom SS, Colopy MW, Brown BW, Strong LC. Accuracy of family history of cancer obtained through interviews with relatives of patients with childhood sarcoma. J Clin Epidemiol 1994;47:89-96.
65. Douglas FS, O'Dair LC, Robinson M, Evans DG, Lynch SA. The accuracy of diagnoses as reported in families with cancer: a retrospective study. J Med Genet 1999;36:309-12.
66. Farrington S, McKinley A, Carothers A, Cunningham C, Bubb J, Sharp L, et al. Evidence for an age-related influence of MSI on colorectal cancer survival. Int J Cancer 2002;98:844-50.
67. Ikenaga M, Tomita N, Sekimoto M, Ohue M, Yamamoto H, Miyake Y, et al. Use of microsatellite analysis in young patients with colorectal cancer to identify those with HNPCC. J Surg Oncol 2002;79:157-65.
68. Gryfe R, Kim I, Hsieh E, Aronson M, Holowaty E, Bull S, et al. Tumor MSI and clinical outcome in young patients with colorectal cancer. New Engl J Med 2000;342:69-77.
69. Planck M, Rambech E, Moslein G, Muller W, Olsson H, Nilbert M. High frequency of microsatellite instability and loss of mismatch-repair protein expression in patients with double primary tumors of the endometrium and colorectum. Cancer 2002;94:2502-10.
70. Seitz JF, Faivre J. La conférence de consensus française sur le cancer du côlon: recommandations simples et précises. Bull Cancer 1998;85:293-4.
71. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-34.
72. Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ. Surveillance improves survival of colorectal cancer in patients with hereditary non-polyposis colorectal cancer. Cancer Detect Prev 2000;24:137-42.
73. Ponz de Leon M, Della Casa G, Benatti P, Percesepe A, di Gregorio C, Fante R, et al. Frequency and type of colorectal tumors in asymptomatic high-risk individuals in families with hereditary nonpolyposis colorectal cancer. Cancer Epidemiol Biomarkers Prev 1998;7:639-41.
74. Heinimann K, Muller H, Weber W, Scott RJ. Disease expression in Swiss hereditary non-polyposis colorectal cancer (HNPCC) kindreds. Int J Cancer 1997;74:281-5.
75. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001;19:4074-80.
76. de Vos WH, Nagengast FM, Griffioen G, Menko FH, Taal BG, Kleibeuker JH, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002;45:1588-94.
77. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-32.
78. Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124:880-8.
79. Lee JH, Kim JW, Cho YK, Sohn CI, Jeon WK, Kim BI, et al. Detection of colorectal adenomas by routine chromoendoscopy with indigocarmine. Am J Gastroenterol 2003;98:1284-8.
80. Rex DK. Accessing proximal aspects of folds and flexures during colonoscopy: impact of a pediatric colonoscope with a short bending section. Am J Gastroenterol 2003;98:1504-7.
81. Dacosta RS, Wilson BC, Marcon NE. New optical technologies for earlier endoscopic diagnosis of premalignant gastrointestinal lesions. J Gastroenterol Hepatol 2002;17:585-104.
82. Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-8.
83. Bensen S, Mott LA, Dain B, Rothstein R, Baron J. The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group. Am J Gastroenterol 1999;94:194-9.
84. Lee JS, Petrelli NJ, Rodriguez-Bigas MA. Rectal cancer in hereditary nonpolyposis colorectal cancer. Am J Surg 2001;181:207-10.
85. Lepisto A, Luukkonen P, Jarvinen HJ. Cumulative failure rate of ileal pouch-anal anastomosis and quality of life after failure. Dis Colon Rectum 2002;45:1289-94.
86. Ky AJ, Sonoda T, Milsom JW. One-stage laparoscopic restorative proctocolectomy: an alternative to the conventional approach? Dis Colon Rectum 2002;45:207-10.
87. Kienle P, Weitz J, Benner A, Herfarth C, Schmidt J. Laparoscopically assisted colectomy and ileoanal pouch procedure with and without protective ileostomy. Surg Endos 2003;17:716-20.
88. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
89. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
90. Dayal M, Barnhart K. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med 2001;19:295-303.
91. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360:942-6.
92. Dove-Edwin I, Boks D, Goff S, Kenter G, Carpenter R, Vasen H, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94:1708-12.
93. Brown G, St John D, Macrae F, Aittomaki K. cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 2001;80:346-9.
94. Percesepe A, Benatti P, Roncucci L, Sassatelli R, Fante R, Ganazzi D, et al. Survival analysis in families affected by hereditary non-polyposis colorectal cancer. Int J Cancer 1997;71:373-6.
95. Bertario L, Russo A, Sala P, Eboli M, Radice P, Presciuttini S, et al. Survival of patients with hereditary colorectal cancer: comparison of HN-PCC and colorectal cancer in FAP patients with sporadic colorectal cancer. Int J Cancer 1999;80:183-7.
96. Tomoda H, Baba H, Akazawa K. Prolonged survival in hereditary non-polyposis colorectal cancer. Oncol Rep 1999;6:321-4.
97. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.